PVLA PDUFA Date: QTORIN rapamycin Page updated November 5, 2026 · next FDA decision on the calendar · Data as of Nov 5, 2026 5:03 AM ET FDA decision (PDUFA) target Feb 28, 2027 · Palvella Therapeutics, Inc. · Microcystic lymphatic malformations
Key facts FDA PDUFA target date 2027-02-28
Drug / candidate QTORIN rapamycin
Indication Microcystic lymphatic malformations
Company Palvella Therapeutics, Inc.
Market-cap tier Mid
New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs .
See every 2027 PDUFA date → All February 2027 PDUFA dates → FAQ When is the PVLA PDUFA date? The FDA PDUFA target date for PVLA (Palvella Therapeutics, Inc.) is 2027-02-28 for QTORIN rapamycin. Dates are company/FDA-sourced and can slip. Verify against primary filings.
What is PVLA's drug QTORIN rapamycin? QTORIN rapamycin is Palvella Therapeutics, Inc.'s candidate under FDA review for Microcystic lymphatic malformations.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.